CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


On-site exercise and educationWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (1)


Name (Synonyms) Correlation
drug1683 On-line exercise and education Wiki 1.00

Correlated MeSH Terms (2)


Name (Synonyms) Correlation
D020370 Osteoarthritis, Knee NIH 0.58
D010003 Osteoarthritis, NIH 0.50

Correlated HPO Terms (2)


Name (Synonyms) Correlation
HP:0005086 Knee osteoarthritis HPO 0.58
HP:0002758 Osteoarthritis HPO 0.50

There is one clinical trial.

Clinical Trials


1 On-line Neuromuscular Exercise and Education for Knee Osteoarthritis

Due to enforced social distancing as a direct consequence of the COVID-19 pandemic, many on-site health care services are unavailable. This study seeks to investigate the relative effectiveness of an alternative on-line delivery model of exercise and education compared to on-site delivery in patients with knee osteoarthritis.

NCT04437134 Knee Osteoarthritis Other: On-line exercise and education Other: On-site exercise and education
MeSH:Osteoarthritis Osteoarthritis, Knee
HPO:Knee osteoarthritis Osteoarthritis

Primary Outcomes

Description: Summary score from the Knee injury and Osteoarthritis Outcome Score, short version (KOOS 12). The summary score is calculated as the average score from the KOOS 12 subscales pain, function and quality of life (QOL), ranging from 0 (worst) to 100 (best).

Measure: Knee impact summary

Time: Primary follow-up point: Change from baseline to completion of GLA:D program (an average of three months). Secondary follow-up point: 12 months

Secondary Outcomes

Description: Fast-paced walking ability is recorded by the physiotherapists and evaluated using the 40-m fast-paced walk test.

Measure: Fast-paced walking ability

Time: Primary follow-up point: Change from baseline to completion of GLA:D program (an average of three months)

Description: Chair-stand ability is recorded by the physiotherapists and evaluated using the 30-s chair-stand test.

Measure: Chair-stand ability

Time: Primary follow-up point: Change from baseline to completion of GLA:D program (an average of three months)

Description: Patients self-report of function during daily life using the subscale function from the KOOS 12 questionnaire with scores ranging from 0 (worst) to 100 (best).

Measure: Self-reported function

Time: Primary follow-up point: Change from baseline to completion of GLA:D program (an average of three months). Secondary follow-up point: 12 months

Description: Patients self-report of pain using the subscale pain from the KOOS 12 questionnaire with scores ranging from 0 (worst) to 100 (best).

Measure: Self-reported pain

Time: Primary follow-up point: Change from baseline to completion of GLA:D program (an average of three months). Secondary follow-up point: 12 months

Description: Patients self-report of quality of life using the subscale quality of life from the KOOS 12 questionnaire with scores ranging from 0 (worst) to 100 (best).

Measure: Self-reported quality of life

Time: Primary follow-up point: Change from baseline to completion of GLA:D program (an average of three months). Secondary follow-up point: 12 months

Description: Mean pain intensity during the last week in the most affected knee is evaluated on a 100 mm visual analogue scale (VAS) with terminal descriptors of 'no pain' (0 mm) and 'maximum pain' (100 mm).

Measure: Pain intensity

Time: Primary follow-up point: Change from baseline to completion of GLA:D program (an average of three months). Secondary follow-up point: 12 months

Description: Patients self-report of time spent (frequency and duration) on structured physical activity and exercise.

Measure: Physical activity and exercise

Time: Primary follow-up point: Change from baseline to completion of GLA:D program (an average of three months). Secondary follow-up point: 12 months

Other Outcomes

Description: Patients self-report of satisfaction with the GLA:D program.

Measure: Patient satisfaction

Time: Primary follow-up point: Completion of GLA:D program (an average of three months). Secondary follow-up point: 12 months

Description: Patients self-reporting if, how and where they have continued exercising.

Measure: Continuation of exercise

Time: Follow-up point: 12 months

Description: Patients self-report their current activity levels using the University of California, Los Angeles (UCLA) activity scale, ranging from 1 (inactive, dependent on others) to 10 (regular participation in high-impact sports).

Measure: Self-reported activity levels

Time: Primary follow-up point: Change from baseline to completion of GLA:D program (an average of three months). Secondary follow-up point: 12 months

Description: Patients self-report of use of acquired skills and knowledge from the GLA:D program.

Measure: Usage of what was learned during GLA:D

Time: Primary follow-up point: Completion of GLA:D program (an average of three months). Secondary follow-up point: 12 months

Description: Patients self-report of how they handle flare-ups in their knee OA symptoms.

Measure: Symptom management

Time: Primary follow-up point: Change from baseline to completion of GLA:D program (an average of three months). Secondary follow-up point: 12 months

Description: Intake of painkillers is evaluated by the physiotherapist asking the patients about intake of any joint related medication. If taking painkillers, the patients are asked which type and whether or not they were taken because of their knee pain.

Measure: Intake of pain killers

Time: Primary follow-up: Change from baseline to completion of GLA:D program (an average of three months).

Description: Patients self-report of sick leave due to knee symptoms.

Measure: Sick leave

Time: Follow-up points: Baseline and 12 months

Description: Patients self-report of their health situation using EuroQol, 5 dimensions, 5 levels (EQ-5D-5L) score (-0.624 to 1; worst to best).

Measure: Health-related quality of life, index score

Time: Primary follow-up point: Change from baseline to completion of GLA:D program (an average of three months). Secondary follow-up point: 12 months

Description: Patients self-report of their health situation using the EuroQol visual analogue scale (EQ VAS), ranging from 0-100 (worst to best).

Measure: Health-related quality of life, visual analogue scale

Time: Primary follow-up point: Change from baseline to completion of GLA:D program (an average of three months). Secondary follow-up point: 12 months

Description: Patients self-report of current knee condition compared to before participation in GLA:D, scored on a 7-point likert scale (much worse to much better).

Measure: Global perceived effect

Time: Primary follow-up point: Completion of GLA:D program (an average of three months). Secondary follow-up point: 12 months

Description: Patients self-report of pain during each exercise session, rated using a numeric pain rating scale (NPRS) 0-10, with zero representing no pain and 10 representing extreme pain.

Measure: Pain during exercise (only for on-line group)

Time: Immediately prior to, and immediately after each exercise session


Related HPO nodes (Using clinical trials)